Market Overview

Yumanity Therapeutics Announces First Clinical Candidate for the Potential Treatment of Parkinson's Disease

Share:

First-in-Human Trials Planned for the Fourth Quarter of 2019

IND-Enabling Studies to Be Completed Utilizing Evotec INDiGO Platform

Yumanity
Therapeutics
, a company focused on discovering transformative
therapies to treat neurodegenerative diseases, today announced its lead
clinical candidate, YTX-7739, is entering IND-enabling studies for the
treatment of Parkinson's disease and related disorders. YTX-7739 is a
novel therapeutic, focused on a novel target newly identified to play a
role in Parkinson's Disease discovered using Yumanity Therapeutics'
proprietary drug discovery platform. YTX-7739 is expected to enter
first-in-human studies by the fourth quarter of 2019.

"In two short years, the team at Yumanity has made unprecedented
progress advancing our lead program to development stage candidate,"
said Ken Rhodes, Ph.D., chief scientific officer, Yumanity Therapeutics.
"Our proprietary discovery platforms have revealed novel targets and
therapeutic approaches to neurodegenerative diseases, enabling us to
bring YTX-7739 forward for development on an accelerated timeframe.
We're excited to initiate our collaboration with Evotec, leveraging the
strength of their INDiGO platform to begin development of
YTX-7739."

Evotec will apply their industry-leading INDiGO platform to support
clinical development of YTX-7739. The INDiGO platform is a component of
Evotec's broad EVT Execute business strategy and accelerates drug
candidates into the clinic by reducing time from nomination to IND
submission to 52 weeks or less. Accelerated development is achieved by
tightly integrating traditional drug development activities into a
single project managed under one roof.

About YTX-7739

YTX-7739 is Yumanity Therapeutics' proprietary lead candidate designed
to inhibit the activity of a novel target that plays an important and
previously unrecognized role in the neurotoxicity caused
by the a-synuclein protein, a major driver of Parkinson's disease and
related neurodegenerative disorders. Misfolding and aggregation of
the a-synuclein protein triggers a cascade of events, ultimately
resulting in neurotoxicity and the subsequent disorders in movement and
cognition that affect people living with these diseases. YTX-7739 has
been shown to inhibit many of the key aspects of a-synuclein toxicity.

About Parkinson's Disease

Parkinson's disease is a progressive neurological disorder that affects
the central nervous system and impacts both motor and non-motor
functions. It is one of the most common age-related neurodegenerative
diseases, affecting an estimated 0.5 to 1 percent of people 65 to 69
years of age, rising to 1 to 3 percent of the population over the age of
80.1 Symptom severity and disease progression differ between
individuals, but typically include slowness of movement (bradykinesia),
trembling in the extremities (tremors), stiffness (rigidity), cognitive
or behavioral abnormalities, sleep disturbances, and sensory dysfunction.2
There is no laboratory or blood test for Parkinson's disease, so
diagnosis is made based on clinical observation.3 Currently,
there is no cure and available treatments only address the symptoms of
Parkinson's disease, not the underlying causes.

About Yumanity Therapeutics

Yumanity Therapeutics is transforming drug discovery for
neurodegenerative diseases caused by protein misfolding. Formed in 2014
by renowned biotech industry leader Tony Coles, M.D., and protein
folding science pioneer Susan Lindquist, Ph.D., the company is focused
on discovering disease-modifying therapies for patients with Alzheimer's
disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS).
Leveraging its three integrated platforms, Yumanity's innovative new
approach to drug discovery and development concentrates on reversing the
cellular phenotypes and disease pathologies caused by protein
misfolding. For more information, please visit yumanity.com.

About Evotec AG

Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with
leading pharmaceutical and biotechnology companies, academics, patient
advocacy groups and venture capitalists. Evotec operates worldwide,
providing the highest quality stand-alone and integrated drug discovery
solutions, covering all activities from target-to-clinic to meet the
industry's need for innovation and efficiency in drug discovery. The
INDiGO platform is a key value-generating component of Evotec's broad
EVT Execute business and represents a logical extension of its broad
discovery platform. INDiGO accelerates early drug candidates into the
clinic by reducing time from nomination to regulatory submission in 52
weeks, and under certain circumstances, even less. Accelerated
development is achieved by tightly integrating traditional drug
development activities into a single project managed under one roof. The
programme has been proven to reduce time and cost while achieving a
quality data package for CTA/IND level regulatory filings. The scale of
this capability means that Evotec works on 10-15 INDiGO's at any one
time. For additional information please go to www.evotec.com
and follow Evotec on Twitter @EvotecAG.

1 N Engl J Med 2003; 348:1356-1364 doi:
10.1056/NEJM2003ra020003

2 J Neurol Neurosurg Psychiatry 2008;79:368–376.
doi:10.1136/jnnp.2007.131045

3 Cold Spring Harb Perspect Med 2012;2:a008870

View Comments and Join the Discussion!